**Oxbryta Lawsuit: Vaso-Occlusive Crisis Claims**

ZAGO 𝕸𝖊𝖉𝖎𝖆

You need 2 min read

·

Post on Oct 23, 2024

49 visitor like this post

Share

Oxbryta Lawsuit: Vaso-Occlusive Crisis Claims

Oxbryta (ingredient: voxelotor) is a medication approved by the FDA for the treatment of sickle cell disease (SCD). While it aims to improve the quality of life for individuals with SCD, concerns have been raised regarding its safety and potential side effects. Recent lawsuits against the manufacturer, Global Blood Therapeutics (GBT), have focused on claims of vaso-occlusive crisis (VOC), a painful and potentially life-threatening complication of SCD.

What is a Vaso-Occlusive Crisis (VOC)?

VOC occurs when sickle-shaped red blood cells block blood flow in the small blood vessels, leading to severe pain, tissue damage, and organ dysfunction. It is one of the most common and serious complications of SCD.

Oxbryta Lawsuit Claims:

The lawsuits alleging VOC as a side effect of Oxbryta claim that:

• Oxbryta increases the risk of VOC: Plaintiffs argue that the drug may actually increase the risk of experiencing VOC, even though it is marketed as a treatment for SCD.
• GBT failed to adequately warn about the risk of VOC: They claim that the manufacturer did not provide sufficient information to patients and healthcare providers about the potential risk of VOC with Oxbryta.
• Patients suffered severe and lasting complications: Many plaintiffs claim that they experienced severe VOC episodes after taking Oxbryta, resulting in long-term health problems, lost wages, and significant pain and suffering.

Key Points of the Oxbryta Lawsuit:

• FDA Warning: The FDA has acknowledged reports of VOC in patients taking Oxbryta, and in 2022 issued a Drug Safety Communication to warn healthcare professionals and patients about the risk.
• Black Box Warning: The medication now carries a Black Box Warning, the most serious type of warning required by the FDA, highlighting the potential risk of VOC.
• Ongoing Investigations: The lawsuits are ongoing, and it remains to be seen what the ultimate outcome will be for both GBT and the patients who have filed claims.

What to Do if You're Concerned About Oxbryta:

If you are taking Oxbryta and experience any of the following, consult your healthcare provider immediately:

• Severe pain
• Swelling
• Fever
• Shortness of breath
• Changes in your vision
• Confusion

These symptoms could indicate a VOC. It's crucial to seek medical attention promptly if you experience any of these signs.

Conclusion:

The Oxbryta lawsuit is a complex legal matter that raises concerns about the safety and efficacy of the drug for SCD patients. While the FDA has acknowledged the potential risk of VOC with Oxbryta, it's essential for individuals with SCD to stay informed and discuss any concerns they may have with their healthcare providers. It's important to weigh the potential benefits and risks of Oxbryta with your doctor and make informed decisions about your treatment plan.